XDx Receives $12.5M Loan Facility from GE Capital, Healthcare Financial Services
Published On January 31, 2011 |
XDx, Inc., a Brisbane, California-based molecular diagnostics company, has received a $12.5m senior secured multi-draw term loan facility from GE Capital, Healthcare Financial Services.
The financing provides the company with working capital to expand the commercialization of its FDA-cleared AlloMap® molecular diagnostic test and pursue the development of other gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases, including lupus.
XDx’s AlloMap Molecular Expression Testing provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management.
The company is led by president and CEO Pierre G. Cassigneul.